Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following table presents selected financial information with respect to the Company’s single operating segment for the years ended:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Collaboration revenue	$	1,614	$	19,570	$	24,122	$	173,384
Less:
Research and development expenses
Direct research and development expenses
ENTR-601-44	7,451		3,561		18,343		9,072
ENTR-601-45	3,543		2,972		10,978		6,098
ENTR-601-50	3,164		2,734		5,896		8,593
ENTR-601-51	2,807		122		6,488		238
Collaboration services	534		1,802		1,937		9,186
Other preclinical and discovery	1,281		1,828		3,762		5,767
Unallocated research and development expenses
Personnel related (including stock-based compensation)	11,549		10,875		37,536		30,687
Facility related and other	8,032		7,363		23,372		22,259
Total research and development expenses	38,361		31,257		108,312		91,900
General and administrative expenses	10,304		9,971		31,500		28,606
Interest and other income	3,571		5,766		11,936		14,346
Provision for (benefit from) income taxes	654		(1,860)		832		2,729
Net (loss) income	$	(44,134)	$	(14,032)	$	(104,586)	$	64,495